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Cdk5, a member of the cyclin-dependent kinase family, has been shown to play an important role in development of the
central nervous system in mammals when partnered by its activator p35. Here we describe the cloning and characterization
of a novel activator of cdk5 in Xenopus, Xp35.2. Xp35.2 is expressed during development initially in the earliest
differentiating primary neurons in the neural plate and then later in differentiating neural tissue of the brain. This is in
contrast to the previously described Xenopus cdk5 activator Xp35.1 which is expressed over the entire expanse of the neural
plate in both proliferating and differentiating cells. Expression of both Xp35.1 and Xp35.2 and activation of cdk5 kinase
occur when terminal neural differentiation is induced by neurogenin and neuro D overexpression but not when only early
stages of neural differentiation are induced by noggin. Moreover, blocking cdk5 kinase activity specifically results in
disruption and reduction of the embryonic eye where cdk5 and its Xp35 activators are expressed. Thus, cdk5/p35 complexes
function in aspects of neural differentiation and patterning in the early embryo and particularly in formation of the
eye. © 1999 Academic PressKey Words: cdk5; Xp35.2; Xenopus; neural; differentiation.
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(INTRODUCTION
Cdk 5 was originally identified as a well-conserved mem-
ber of the cyclin-dependent kinase family of proteins (Mey-
erson et al., 1992). The prototypical cdks play pivotal roles
n regulating cell cycle transitions when bound to their
pecific activators, the cyclins. In contrast, mammalian
dk5 is expressed predominantly in postmitotic cell popu-
ations where it is found complexed not to cyclins but to
embers of a new class of activator, typified by the protein
35 (Ishiguro et al., 1994; Lew et al., 1994; Tsai et al., 1994).
p35 itself is expressed predominantly in postmitotic neu-
rons of the central nervous system and its presence corre-
lates well with demonstrated cdk5 kinase activity (Lew et
al., 1994; Tsai et al., 1994; Zheng et al., 1998).
The expression pattern of active cdk5, found in postmi-
otic cells particularly in the central nervous system, is
ndicative of an important function in neural differentiation
1 To whom correspondence should be addressed at current ad-
dress: Department of Oncology, Box 193, Addenbrooke’s Hospital,
Hills Road, Cambridge, CB2 2QQ, England. Fax: (01223) 412213.
E-mail: ap113@hermes.cam.ac.uk.
001
Co
Allr patterning. This role was confirmed by demonstrating
hat neurons in primary cortical cultures which were trans-
ected with a dominant negative cdk5 construct had a
pecifically reduced propensity to elaborate neurites (Ni-
olic et al., 1996). In contrast, neurons expressing increased
evels of cdk5 and p35 showed enhanced neurite outgrowth.
ore recently a cdk5 null mouse has been reported which
xhibits perinatal lethality with extensive defects in the
entral nervous system including lack of stratification in
he neocortex and lack of foliation in the cerebellum
Ohshima et al., 1996). A p35 null mouse has also been
generated which displays a more subtle phenotype; while
adults are viable and fertile they suffer from seizures (Chae
et al., 1997). Microscopic examination reveals disruption of
the cortical laminar structure due to failure of the newly
differentiated neurons to migrate past older neurons to take
up their more usual superficial position, as well as a
number of additional subtle neural defects. The cdk5 null
mouse has a more severe phenotype than that of the p35
null mouse, raising the possibility of the existence of other
activating partners. Indeed, another p35 family member,
p39, has been identified which has an expression pattern in2-1606/99 $30.00
pyright © 1999 by Academic Press
rights of reproduction in any form reserved. 119
n
m
c
d
d
l
t
t
o
c
f
a
S
c
o
t
l
c
m
t
T
T
t
W
a
X
120 Philpott, Tsai, and Kirschnerthe central nervous system distinct from that of p35 (Tang
et al., 1995; Zheng et al., 1998).
While it is clear that cdk5/p35 plays an important role in
eurogenesis in the early embryo, the limitations of the
ouse for studying early embryonic stages makes it diffi-
ult to study the precise role of this complex in neural
ifferentiation. To look at these early processes in more
etail, we have turned to embryos of the frog Xenopus
aevis. These have a number of advantages as an experimen-
al system for studying early neurogenesis, most notably
he large size of the embryos, the fact that they develop
utside the mother, and the potential for use of explant
ulture systems to study neural differentiation in isolation
rom other patterning events.
Cdk5 has been cloned in Xenopus and it shows 97%
mino acid homology to its rat counterpart (Gervasi and
zaro, 1995), indicating a high potential for functional
onservation. Xcdk5 is widely expressed throughout tissues
f the early tadpole (Philpott et al., 1997). We have cloned
wo p35 activators of cdk5 from Xenopus embryonic cDNA
ibraries. Surprisingly one, Xp35.1, is expressed in dividing
ells of mesodermal and neural lineage early in develop-
ent and later remains strongly expressed in the brain and
he myotome (Philpott et al., 1997). Blocking cdk5 kinase
activity in the early embryo by microinjection of a domi-
nant negative cdk5 construct results in disruption of myo-
tomal muscle. Moreover, experiments investigating the
induction of muscle in embryonic animal pole explants
(animal caps) in response to the TGF-b family member
activin demonstrate that cdk5 kinase activity is required for
expression of myogenic genes and muscle markers that are
turned on as differentiation of muscle progresses (Philpott
et al., 1997).
These studies demonstrated a new role for cdk5 in
regulation of muscle differentiation but failed to address a
role for this kinase in neurogenesis in the early Xenopus
embryo. As described previously, Xp35.1 is expressed over
the entire expanse of the neural plate in both proliferating
and differentiating cells (Philpott et al., 1997). In contrast,
we have also cloned a p35 homologue in Xenopus, Xp35.2,
described in this study, which is expressed solely in differ-
entiating neurons. We find that cdk5 kinase is activated in
animal pole explants which are induced to form terminally
differentiated neurons and that this is accompanied by the
increased expression of both Xp35.1 and Xp35.2, and cdk5.
However, induction of only the early stages of neural
differentiation, as induced by noggin, is not sufficient to
activate cdk5 kinase. Blocking cdk5 kinase activity does
not alter expression of markers of either early or late neural
differentiation in the intact embryo or in explant culture
indicating that cdk5 does not act at the level of expression
of neural-specific genes. This contrasts with the demon-
strated role of cdk5 in regulating expression of muscle-
specific genes (Philpott et al., 1997). However, blocking
cdk5 kinase activity in the embryo does result in specific
reduction and disruption of the eye confirming an impor-
tant role of cdk5/p35 in differentiation and patterning of
Copyright © 1999 by Academic Press. All rightthis predominantly neural structure. Thus, cdk5 kinase
may play an important role in terminal differentiation and
patterning of embryonic neural structures in Xenopus but
not in the specification of proneural domains.
MATERIALS AND METHODS
Library Screening
The library screening method used to isolate Xp35.2 (Fig. 1) is
described in detail elsewhere (Philpott et al., 1997).
H1 Kinase Assay
Embryos were left uninjected or injected with RNAs described.
Two whole embryos were homogenized at stage 13 (Fig. 2) in 200 ml
IP buffer (Philpott et al., 1997). Cdk5 was immunoprecipitated
from cleared homogenates using the C-terminal C8 antibody (Santa
Cruz) and these immunoprecipitates were tested for their ability to
phosphorylate histone H1 exactly as described in Philpott et al.
(1997).
Extracts from animal caps (Figs. 5 and 7, 500, or 200 mg total
protein, respectively) were assayed for cdk5 kinase activity as
described in Tsai et al. (1993).
RT-PCR Analysis
RT-PCR analysis was performed as described previously (Lustig
and Kirschner, 1995; Lustig et al., 1996; Philpott et al., 1997).
Novel primer sequences are provided. Xp35.2: forward, 59-
CAAGCGGTGCCAGGGAG- 39; reverse, 59-TCTGTTCCAG-
GGGGC- 39.
The primer sequences for neural b-tubulin and NCAM were
aken from the Xenopus molecular marker resource on the World
ide Web (http://vize 222@zo.utexas.edu). Neural b-tubulin was
mplified for 30 cycles and NCAM was amplified for 21 cycles.
p35.2 was amplified for 30 cycles.
Embryos and Explants
Embryos were injected and animal caps cut and cultured as
described in Philpott et al. (1997). Caps were cultured until sibling
embryos had reached stage 25 (Fig. 5) or stage 28 (Fig. 7) or as
described in the figure legend to Fig. 6.
In Situ Hybridization, Sectioning, and Staining
Whole-mount in situ hybridization was performed as described
in Harland (1991) using digoxigenin–11-UTP-labeled probes (Boehr-
inger). The antisense probe for full-length Xp35.2 was synthesized
using T7 polymerase and a Bluescript vector. 4-Nitroblue tetrazo-
lium chloride (NBT) and 5-bromo-4-chloro-indolyl-phosphate,
4-toluidine salt (BCIP) were used as substrates for the color reaction
giving purple staining. Stained embryos were viewed in whole
mount either uncleared (Figs. 4Ai and 4Aii, Fig. 8a) or cleared with
benzoyl benzoate:benzoic acid at 2:1 (Fig. 4Aiii). Where appropri-
ate, embryos were fixed in MEMFA (Harland, 1991) overnight after
staining, embedded in JB4 plastic resin, and sectioned (Fig. 4B).
Alternatively, stage 35/36 embryos (Fig. 8b) were fixed in MEMFA,
embedded in Paraplast medium (Oxford Labware), sectioned sagi-
s of reproduction in any form reserved.
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121Xp35.2, Cdk5, and Neuronal Differentiation in Xenopustally, and then stained with hemotoxylin and eosin and mounted in
Permount (Sigma). Detection of b-galactosidase activity was by the
ethod of Vize et al. (1991).
Constructs
Human cdk5 wild-type (WT) and cdk5 dominant negative (DN)
(Meyerson et al., 1992; van den Heuvel and Harlow, 1993) includ-
ing a C-terminal HA tag cloned into pCS21 (Turner and Wein-
raub, 1994) are as described in Philpott et al. (1997) and were used
hroughout this study. Xp35.2 was cloned into the XhoI and XbaI
ites of pCS2 MT1 and used for in vitro transcription using SP6
olymerase. Xp35.1, neurogenin, neuro D, and noggin were ex-
ressed from CS21 vectors using SP6 polymerase.
RESULTS
Cloning a New Kinase Activator of cdk5, Xp35.2
FIG. 1. Xp35.2 is a novel member of the p35 family of cdk5 kina
Xp35.2. (B) Sequence alignment between Xp35.2, Xp35.1, the other
the N- and C-terminal domains are highly conserved there is a subst
human p35 and from Xp35.1.To identify homologues of human p35 we screened a
stage 28 Xenopus embryo head library at low stringency
t
Copyright © 1999 by Academic Press. All rightith partial human p35 cDNA (Tsai et al., 1994) coding for
he carboxy-terminal 600 bp (Philpott et al., 1997). After
screening 500,000 plaques, two positive clones were ob-
tained. One of these coded for the partial reading frame of
Xp35.1, described in detail by Philpott et al. (1997). The
second clone had a 2.5-kb insert which contained the full
open reading frame for a protein of 293 amino acids with
molecular weight 32.8 kDa which showed significant ho-
mology to human p35 across extensive portions of the
molecule. Xp35.2 shows 79% amino acid identity with
human p35 across its entire length. This compares with
68% identity between Xp35.1 and human p35. This indi-
cates that Xp35.2 may be the true Xenopus homologue of
uman p35 and this conclusion is strengthened by the
p35.2 localization pattern presented below. Xp35.2 is 64%
dentical to Xp35.1 and this similarity is found mainly in
he highly conserved C-terminal cdk5 binding and activa-
tivators. (A) Full nucleotide sequence and amino acid sequence of
d Xenopus cdk5 kinase activator, and human p35. Note that while
l divergence in the central domain of the Xp35.2 protein, both fromse ac
cloneion domain (76% identity at the amino acid level).
To demonstrate that both Xp35.1 and Xp35.2 are bona
s of reproduction in any form reserved.
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122 Philpott, Tsai, and Kirschnerfide activators of cdk5 kinase we injected RNA coding for
full-length Xp35.1 or Xp35.2 into fertilized Xenopus eggs.
Embryos were allowed to develop until stage 13 when
extracts were prepared (see Materials and Methods). Endog-
enous cdk5 was immunoprecipitated from these lysates and
tested for its ability to phosphorylate the model substrate
histone H1. Immunoprecipitated cdk5 from stage 13 em-
bryos is largely inactive (Fig. 2, lane 3), most likely due to
the low level of endogenous activators. However, overex-
pression of Xp35.1 or Xp35.2 results in generation of sub-
stantial cdk5 kinase activity as measured by histone H1
phosphorylation (Fig. 2, lanes 1 and 2). Thus, both Xp35.1
and Xp35.2 can activate cdk5 kinase.
Anh-myc immunoprecipitates of myc-tagged Xp35.1 and
Xp35.2 expressed from RNAs injected into embryos are also
highly active in phosphorylating histone H1 (data not
shown) demonstrating that both Xp35.1 and Xp35.2 are able
to activate cdk5 kinase activity directly.
Xp35.2 Expression during Embryogenesis
We have used quantitative reverse-transcription PCR
analysis to examine developmental expression of Xp35.2
FIG. 2. Both Xp35.1 and Xp35.2 are able to activate cdk5 kinase
ctivity. One nanogram RNA encoding myc-tagged Xp35.1 (lane 1)
r Xp35.2 (lane 2) was injected into fertilized eggs. Uninjected
mbryos were used as controls (lane 3). At stage 13 extracts were
roduced from two injected embryos and cdk5 was specifically
mmunoprecipitated. These immunoprecipitates were tested for
heir ability to phosphorylate the model substrate histone H1.
FIG. 3. Developmental expression of Xp35.2. Two micrograms of
a 20-ml reaction. One microliter per lane was used for quantitative
ecarboxylase, expressed constantly through development, was also use
Copyright © 1999 by Academic Press. All rightranscripts using ornithine decarboxylase as a loading con-
rol. Xp35.2 is barely detectable before the midblastula
ransition and although levels rise somewhat after MBT,
hey remain relatively low until tailbud stages. (Slight
uctuations seen in early stages are not reproducible and
robably reflect slight variations of detection of messages at
hese low levels.) At around stage 23 transcript levels
ncrease dramatically and plateau soon afterward. Notably,
any cell types including neurons are undergoing extensive
ifferentiation at this time (Hartenstein, 1989; Jacobson and
uang, 1985). Interestingly, Xp35.1 which is first expressed
fter MBT shows greater expression in earlier developmen-
al stages when embryonic tissues are still proliferating but
ts expression rises more gradually than Xp35.2 during the
ater stages of tadpole development (Philpott et al., 1997).
To determine the spatial expression of Xp35.2 during
arly embryogenesis we performed in situ hybridization
nalysis. In agreement with RT-PCR data, Xp35.2 was
ndetectable over background in blastula and gastrula em-
ryos. However, by mid-neural plate stages Xp35.2 is
learly detected in two anterior regions that correspond to
rigeminal placodes (Fig. 4Ai, labeled TG). In addition,
p35.2 is expressed symmetrically in two stripes on either
ide of the midline in the neural plate. Staining is strongest
n the more lateral stripes characteristic of expression in the
rimary motor neurons, the first neurons to exit from the
ell cycle and differentiate (Hartenstein, 1989; Jacobson and
uang, 1985). Expression is also detected in two medial
tripes which correspond to primary sensory neurons.
p35.2 is not clearly seen in the potential third stripe of
rimary interneurons, although such staining could be
eak and obscured by background staining. In addition,
taining of the stripe of primary sensory neurons is rela-
ively wide, which may further obscure any interneuron
taining. Figure 4Aii shows the dorsal view of an early
ailbud-stage embryo. Again, Xp35.2 is present in two
tripes symmetrically arranged with respect to the midline
n either side of the closed neural tube indicative of
taining in the primary neurons. Staining is also prominent
n nerves leaving the neural tube to enter the otic vesicles
arrow) and nerves emerging from the trigeminal ganglia
from developmentally staged embryos was reverse transcribed inRNA
RT-PCR analysis using primers specific for Xp35.2. Ornithine
d as a loading control.
s of reproduction in any form reserved.
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123Xp35.2, Cdk5, and Neuronal Differentiation in Xenopus(data not shown). Figure 4Aiii shows a late tailbud-stage
embryo which has been cleared to view Xp35.2 staining in
the brain. In agreement with RT-PCR data, Xp35.2 expres-
sion has increased dramatically by this stage. Message
remains throughout the entire length of the neural tube
(data not shown) but is strongest anteriorly in the forebrain,
midbrain, and hindbrain and in the cranial nerves. A con-
spicuous area of reduced staining at the back of the mid-
brain corresponds to the posterior tectum, a zone where
cells are constantly being generated, and thus represents an
area of reduced differentiation.
Thus, Xp35.2 is expressed exclusively in differentiating
neurons in the Xenopus embryo. This expression of Xp35.2
FIG. 4. Xp35.2 is specifically expressed in differentiating neural ti
a digoxigenin-labeled Xp35.2 antisense probe, visualized in purple a
of neural plate stage, (Aii) dorsal view of early tailbud, and (Aiii) l
trigeminal ganglion (TG) is highlighted with an arrow. (B) A section
been detected by whole-mount in situ hybridization and then the
neurons of the forebrain (thick arrow) and ganglion cells of the retis in contrast to that of the closely related Xp35.1 which is
expressed over the entire expanse of the neural plate during
o
d
Copyright © 1999 by Academic Press. All rightarlier neurula stages when most cells in the region retain
heir proliferative capacity and which is expressed later
hroughout the closed neural tube (Philpott et al., 1997;
ata not shown). Thus, it seems that Xp35.2 rather than
p35.1 may be more analogous to mammalian p35 which is
xpressed exclusively in populations of differentiating neu-
ons which have exited the cell cycle in the central nervous
ystem (Lew et al., 1994; Tsai et al., 1994).
Figure 4B shows Xp35.2 expression in a cross-section of
he head of a tailbud-stage embryo. Strong expression in the
rimary differentiating neurons is visible in outer layers of
he forebrain (thin arrows) while Xp35.2 is also strongly
xpressed in the retina (thick arrow). Staining is strongest
Albino embryos were used for in situ hybridization analysis using
st a white/pink background. Embryonic stages are (Ai) dorsal view
l view of the head of a late tailbud-staged embryo. Staining of the
ugh the head of a stage 35/36 embryo where Xp35.2 expression has
yo has been sectioned. Xp35.2 staining is strong in differentiating
thin arrows).ssue.
gain
atera
thron the vitreal surface of the retina where ganglion cells are
ifferentiating. These ganglion cells are the first cells to
s of reproduction in any form reserved.
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124 Philpott, Tsai, and Kirschnerdifferentiate in the embryonic eye (Holt et al., 1988). We
have also seen that Xp35.1 is strongly expressed in the lens
(Philpott et al., 1997; data not shown), while cdk5 is
xpressed throughout the eye (Philpott et al., 1997). This
raises the possibility that cdk5, partnered by both Xp35.1
and Xp35.2, could play a role in development and differen-
tiation of a number of tissues in the embryonic eye (see
below). Cdk5, p35, and p39 are all strongly expressed in
neural components of the embryonic eye of the rat as well
as in the lens (Zheng, 1998, #41; Gao et al., 1997).
Neural Inducers Can Activate cdk5
We have shown previously that cdk5 kinase is activated
in animal caps induced to form mesoderm by the TGF-b
family member activin but not in animal caps which have
followed the default pathway of epidermal differentiation
(Philpott et al., 1997). We wished to determine whether
nducers of neural commitment and differentiation would
lso induce cdk5 kinase activity using this animal cap
xplant system. To induce formation of neural tissue in
nimal caps we have used noggin, an extracellular inhibitor
f the BMP signaling pathway which induces animal caps to
nter down a proposed default pathway of neural induction
Zimmerman et al., 1996). In addition, we have used ectopic
expression of the neurogenic genes neurogenin and neuro D
which act to induce the formation of neural tissue directly
by activating transcription of neuralizing genes (Lee et al.,
1995; Ma et al., 1996). In contrast to the relatively undif-
ferentiated neural tissue induced by overexpression of nog-
gin, neurogenin and neuro D overexpression results in the
formation of neural tissue containing discrete neurons that
display many characteristics of terminal differentiation.
Fertilized Xenopus eggs were either left untreated or
injected with RNA coding for neurogenin, neuro D, or
noggin. At stage 8.5–9 animal caps were cut and cultured
while a sample of uninjected caps was incubated in activin
at 2 ng/ml. Animal caps were collected when parallel
embryos had reached stage 25 and RNA from six caps was
reverse transcribed into cDNA for RT-PCR analysis. Pro-
tein extracts were prepared from the remaining caps, the
endogenous cdk5 immunoprecipitated, and kinase activity
measured by the ability of the immunoprecipitate to phos-
phorylate the model substrate histone H1.
Figure 5, lane 1 shows that untreated animal caps that
have followed the default pathway to epidermal differentia-
tion have low levels of cdk5 kinase activity. In contrast,
caps that have been induced to form differentiating neurons
by injection of neurogenin and neuro D show seven- and
fourfold enhancement of cdk5 kinase activity, respectively
(Fig. 5, lanes 2 and 3). In marked contrast to neurogenin and
neuro D which induce terminal neural differentiation,
noggin, which induces only the early stages of neural
commitment and differentiation (Lamb et al., 1993), is
unable to induce the activation of cdk5 kinase (lane 4).
Activin treatment also activates cdk5 as described previ-
ously (Philpott et al., 1997), although this enhancement is
Copyright © 1999 by Academic Press. All rightmodest compared to that seen with neurogenin and neuro D
(lane 6). Thus, we demonstrate that neurogenin and neuro
D, but not noggin, are able to activate cdk5 kinase activity.
This does not reflect an inability of noggin to induce at least
the early stages of neural differentiation. Figure 5B shows
FIG. 5. Cdk5 kinase is activated by inducers of terminal neural
differentiation. (A) Embryos were left uninjected (lanes 1, 5, and 6)
or injected with RNA encoding neurogenin (50 pg, lane 2), neuro D
(500 pg, lane 3), or noggin (25 pg, lane 4). Animal caps were cut at
stage 8.5 and incubated in 0.73 MMR without (lanes 1–4) or with
(lane 5) activin at 2 ng/ml. Animal caps were aged until parallel
embryos had reached stage 25 and whole embryos at this stage were
also taken as a control (lane 6). Protein extracts were prepared and
cdk5 was then specifically immunoprecipitated. Immunoprecipi-
tates were tested for their ability to phosphorylate the model
substrate histone H1. (B) Alternatively, six animal caps produced
and aged until stage 25 exactly as described above were used for
RT-PCR analysis to determine the expression of the pan-neural
marker NCAM and the ubiquitously expressed EF1a message
hich is used as a loading control. Uninjected embryo (lane 1) or
mbryos injected with RNA encoding neurogenin (50 pg, lane 2),
euro D RNA, (500 pg, lane 3), or noggin (25 pg, lane 4).the result of RT-PCR analysis of animal caps from embryos
injected with noggin, neurogenin, and neuro D RNA. All
s of reproduction in any form reserved.
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125Xp35.2, Cdk5, and Neuronal Differentiation in Xenopusthree genes are able to induce robust expression of the early
neural marker NCAM.
Induction of cdk5 and Activators by Neuralizing
Genes
We wished to determine whether neurogenin and neuro
D activated cdk5 kinase activity in this animal cap assay by
inducing the expression of cdk5 and/or its activators Xp35.1
and Xp35.2. In a similar experiment to that described in the
legend to Fig. 5, we injected fertilized eggs with RNA
encoding neurogenin, neuro D, and noggin. Animal caps
were cut at stage 8.5 and harvested at stage 13, stage 19, and
stage 26 (as labeled in Fig. 6). Isolated RNA was reverse
transcribed into cDNA and quantitative RT-PCR analysis
was performed to determine the expression level of cdk5,
Xp35.1, and Xp35.2 as well as that of the neural markers
FIG. 6. Xp35.1, Xp35.2, and Xcdk5 expression is induced by
neurogenic genes. Embryos were left uninjected (lanes 1–3) or
injected with 25 pg noggin (lanes 4–6), 50 pg neurogenin (lanes
7–9), or 500 pg neuro D (lanes 10–12) RNA. Animal caps were cut
at stage 8.5 and then aged until stage 13 (lanes 1, 4, 7, and 10), stage
19 (lanes 2, 5, 8, and 11), or stage 26 (lanes 3, 6, 9, and 12). cDNAs
were prepared from caps and assayed by quantitative RT-PCR
analysis for expression of Xp35.1, Xp35.2, cdk5, NCAM, and neural
b-tubulin as labeled. EF1a expression was used as a loading control.neural b-tubulin and NCAM. EF1a expression was used as
a loading control. Signals were quantitated by phosphoim-
Copyright © 1999 by Academic Press. All rightage analysis to give an approximation of fold induction of
gene expression over that seen in the uninjected control
caps.
Xp35.1, Xp35.2, and cdk5 were expressed at low but
detectable and constant levels in uninjected animal caps at
all three stages indicating that, as expected, these genes are
not specifically induced on epidermal differentiation. Both
neurogenin and neuro D give strong induction of neural
b-tubulin even by stage 13 (both approximately 30-fold over
uninjected controls), rising further during development.
Neurogenin and neuro D overexpression resulted in a
similar level of neural gene induction and had a similar
effect on Xp35.1, Xp35.2, and cdk5 expression. Both neuro
D and neurogenin enhance expression of cdk5 only signifi-
cantly by stage 26 (approximately 10- to 12-fold, respec-
tively). However, their effect on Xp35.1 and Xp35.2 can
even be seen as early as stage 13 where Xp35.1 expression is
increased 2-fold by neurogenin while Xp35.2 RNA level is
enhanced 6-fold by both neurogenin and neuro D. By stage
26, Xp35.1 is more than 2.5 times more highly expressed in
neurogenin- and neuro D-injected caps than the uninjected
controls. More dramatically, by stage 26 Xp35.2 expression
levels increase by approximately 15-fold over the unin-
jected control in the presence of neurogenin and neuro D.
Noggin injection induced robust expression of NCAM in
animal caps even by stage 13 that remained constant until
stage 26. Interestingly, under these conditions, and in
contrast to previous reports (Ferreiro et al., 1994; Lamb et
al., 1993; Papalopulu and Kintner, 1996), noggin did induce
a low level of neural tubulin expression even by stage 13
(approximately 2-fold) and by stage 26 this was as much as
30-fold increased, although neural b-tubulin expression was
always considerably lower than that seen with neurogenin
or neuro D. The enhancement of neural b-tubulin by
oggin, especially at later times seen here, may reflect the
omparatively lengthy aging of animal caps in this experi-
ent (Lamb and Harland, 1995; Papalopulu and Kintner,
996). However, even given this increase in b-tubulin
xpression induced by noggin, cdk5, Xp35.1, and Xp35.2
evels are completely unaffected.
Thus, neurogenin and neuro D induce cdk5 kinase activ-
ty probably via the increased expression of cdk5 itself as
ell as its activating partners Xp35.1 and Xp35.2. It is
nteresting to note that these neurogenic genes induce the
xpression of Xp35.2 more strongly than Xp35.1, and
p35.2 in contrast to Xp35.1 is found exclusively in differ-
ntiating neurons. In contrast, Xp35.1 and Xp35.2 expres-
ion is not induced by noggin which has limited ability to
nduce terminal differentiation of neurons.
Cdk5 Kinase Activity Is Not Required for Neural
Gene Expression
Cdk5 has been shown to have a largely cytoplasmic
function in mammalian neurons (Nikolic et al., 1996; Tsai
et al., 1993) where it has a potential role in cytoskeletal
regulation during axonal outgrowth phosphorylating sub-
s of reproduction in any form reserved.
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126 Philpott, Tsai, and Kirschnerstrates such as tau and MAP 2 (Lew and Wang, 1995).
However, we have demonstrated that cdk5 kinase in Xeno-
pus embryos functions to regulate the expression of myo-
genic genes; expression of the cdk5 dominant negative
mutant in animal caps downregulates expression of the
myogenic genes Myo Db and MRF 4 as well as the muscle
marker muscle actin (Philpott et al., 1997). In Fig. 6 we have
demonstrated that neurogenin and neuro D are able to
induce the expression of both cdk5 and its Xp35 partners as
well as markers of early and late neural differentiation.
Therefore, it is possible that these neurogenic genes require
cdk5 kinase activity to upregulate neural gene expression
by analogy to the requirement for cdk5 kinase activity to
activate muscle gene expression in Xenopus. To address
this question, we have used a mutant of cdk5 which can
bind p35 activators but is kinase inactive and thus acts as a
dominant negative when injected into Xenopus embryos
Nikolic et al., 1996). This was used to demonstrate a
equirement for cdk5 kinase in muscle differentiation (Phil-
ott et al., 1997). Embryos were injected either with neu-
rogenin or neuro D alone or in combination with RNA
encoding cdk5 or cdk5 dominant negative (cdk5 DN).
Animal caps were cut from these embryos at stage 8.5 and
aged until parallel embryos had reached stage 28. RNAs
were prepared from these animal caps, reverse transcribed
into cDNAs, and then used as templates for quantitative
RT-PCR analysis to detect NCAM and neural b-tubulin
xpression, markers of early and late neural differentiation,
espectively. Animal caps cut from uninjected embryos
Fig. 7A, lane 1) expressed virtually no NCAM or b-tubulin.
In contrast, both neurogenin and neuro D induced robust
levels of expression of both markers (lanes 2 and 5). Injec-
tion of either wild-type (lanes 3 and 6) or dominant negative
(lanes 4 and 7) cdk5 had no significant effect on expression
levels of NCAM or b-tubulin.
The injected cdk5 DN is working efficiently to block
ndogenous cdk5 kinase activity in this assay. Figure 7B
hows cdk5 kinase activity of cdk5 immunoprecipitates
rom extracts of uninjected animal caps (lane 1), animal
aps injected with neurogenin (lane 2), or animal caps
njected with neurogenin and cdk5 DN (lane 3). As ex-
ected, ectopic neurogenin expression leads to activation of
dk5 kinase even in stage 28 caps and this can be efficiently
locked by coinjection of cdk5 DN. Thus, cdk5 does not
ppear to play a role in regulating neurogenin- or neuro
-mediated control of neural gene expression.
Cdk5 Kinase Activity Is Required for Normal Eye
Formation in the Xenopus Embryo
We have shown previously that cdk5 kinase activity is
required for normal development and patterning of the
myotome in early embryos. In addition, we saw that em-
bryos expressing cdk5 DN clearly showed some disruption
of head neural structures, particularly the eye (Philpott et
al., 1997; data not shown). We wished to investigate more
closely the effect of blocking cdk5 kinase activity on g
Copyright © 1999 by Academic Press. All rightevelopment of neural structures in the early embryo. A
otal of 2.5 ng of either cdk5 WT or cdk5 DN RNA was
njected into one dorsal cell of a four-cell embryo in the
nimal hemisphere, along with 0.5 ng b-galactosidase RNA
which acts as a tracer for injected gene expression, the
uninjected side of the embryo acting as an internal control.
Embryos were allowed to develop until the tailbud stage
when they were fixed and stained for Xgal expression.
Embryos in which injections had been correctly targeted to
the dorsal head and neural tube regions were then subjected
FIG. 7. Cdk5 kinase activity is not required for expression of
neural markers. (A) Embryos were either left uninjected (lane 1) or
injected with 50 pg neurogenin (lanes 2–4) or 500 pg neuro D (lanes
5–7) RNA. These RNAs were either injected alone or in combina-
tion with 2 ng cdk5 WT RNA (lanes 3 and 6) or 2 ng cdk5 DN RNA
(lanes 4 and 7). Animal caps were cut when embryos had reached
stage 8.5 and aged until parallel embryos had reached stage 28.
cDNAs were then prepared and quantitative RT-PCR analysis was
used to detect expression of the neural markers NCAM and neural
b-tubulin and the ubiquitous EF1a, used as a loading control. (B)
mbryos were left uninjected (lane 1) or injected with 50 pg
eurogenin (lane 2) or 50 pg neurogenin with 2 ng cdk5 DN (lane 3).
nimal caps were cut at stage 8.5 and then aged until parallel
mbryos had reached stage 28. Protein extracts were prepared,
ndogenous cdk5 was immunoprecipitated as described under
aterials and Methods, and the immunoprecipitates were tested
or their ability to phosphorylate the model substrate histone H1.to in situ hybridization to detect several regional and
eneral neural markers. Expression of the early regional
s of reproduction in any form reserved.
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neural markers Otx-2 [expressed in forebrain and midbrain
(Pannese et al., 1995)] and En 2 [expressed at midbrain/hind
brain boundary (Brivanlou and Harland, 1989; Hemmati-
Brivanlou et al., 1991)] was unaffected by expression of
either WT or DN cdk5 (data not shown), indicating that
cdk5 is not required for early anteroposterior patterning of
the neural tube.
Given that cdk5 kinase activity and enhanced expression
of its activators only become apparent on neural differen-
tiation in animal caps, we wished to determine whether
blocking cdk5 kinase activity affected the expression pat-
tern of a marker for terminal differentiation, neural
b-tubulin. In agreement with animal cap experiments,
expression of neural b-tubulin was largely unaffected in
areas of the neural tube where cdk5 kinase activity was
blocked by cdk5 DN expression (data not shown). However,
the majority of embryos injected with cdk5 DN showed a
substantial reduction in the size of the eye in the expressing
area and infrequently nerves of the trigeminal ganglia were
lost on the injected side (data not shown, but see Fig. 8).
To investigate this phenotype more closely, we injected
embryos with 2.5 ng cdk5 WT or DN into the animal
hemisphere of two dorsal cells of a four-cell embryo along
with the lineage tracer b-galactosidase. These embryos
were then stained for expression of Pax 6 and also with Xgal
as a marker of the injected region. Pax 6 is a homeobox-
containing transcription factor which has been shown to be
intimately involved in eye development in the Xenopus
tadpole and acts as a good marker for eye development even
at early stages before these organs are fully formed (Hirsch
and Harris, 1997). Embryos overexpressing cdk5 WT devel-
oped normally compared to uninjected controls (Fig. 8a) and
had two large eyes staining strongly for Pax 6. In contrast,
embryos injected with cdk5 DN were stunted along the
anteroposterior axis as observed previously (Philpott et al.,
1997). In addition, these embryos showed significantly
reduced eyes as determined by visual inspection and as
delineated by Pax 6 staining. To demonstrate that this
reduction in eye size was specific for blocking cdk5 kinase
activity, we performed a rescue experiment where cdk5 WT
RNA was injected along with cdk5 DN RNA. This combi-
nation largely rescued the eyes as judged by extent of Pax 6
staining (Figs. 8a and 8b), demonstrating the specificity of
the small eye phenotype seen when cdk5 kinase activity is
blocked. When embryos were injected into one cell of a
two-cell embryo with cdk5 DN RNA, reduction of the eye
was frequently seen but only on the injected side of the
embryo (data not shown).
Cdk5 has been shown to associate with cyclin D1 (Xiong
et al., 1992). Although these complexes have not demon-
strated H1 kinase activity, phosphorylation of unknown
substrates cannot be ruled out. Cyclin D1 is expressed at
high levels in the Xenopus eye (T. Hunt, personal commu-
nication) and it is possible that cyclin D1 and cdk5 do
function together in eye formation. To test this possibility,
we coexpressed Xenopus cyclin D1 (a generous gift of T.
Hunt) along with cdk5 DN to see whether this would
rescue the small eye phenotype that results from injection
of cdk5 DN alone. We found that embryos injected with
cyclin D1 along with cdk5 DN still had eyes of reduced size
(data not shown). This failure to rescue the small eye
phenotype seen when cdk5 kinase activity is blocked using
the dominant negative construct indicates that its function
in eye development is independent of any ability to interact
with cyclin D1.
Cdk5 Dominant Negative Expression Gives
Morphological Disruption of Eyes
We wished to determine whether embryos expressing
cdk5 DN had correctly formed but merely reduced eyes or
whether eye structure was disrupted, similar to the disrup-
tion seen in myotomal muscle when cdk5 kinase activity is
blocked. Five nanograms of cdk5 WT and/or cdk5 DN were
injected into two dorsal cells of a four-cell embryo which
was allowed to develop until stage 35/36 and then fixed and
sectioned to investigate eye morphology. Cdk5 WT-injected
embryos showed normal, well-organized eyes which were
indistinguishable from those in the uninjected embryo (Fig.
8biii). In contrast, embryos expressing cdk5 DN showed
eyes of reduced size which were substantially disrupted
(Fig. 8bii). Although the lens was present, it was smaller and
often misshapen. Additionally, in cdk5 DN-injected em-
bryos the retina appeared to be of normal thickness but edge
to edge distance was reduced giving rise to a smaller eye.
Strikingly, tissues of the retina did not display their usual
sharp vitreal boundary but instead showed disorganization
in these regions. This was consistently seen with cdk5
DN-expressing embryos and could be rescued by coinjec-
tion of cdk5 WT (see below) and thus cannot be accounted
for by sectioning artifacts. Interestingly, this disruption of
tissue boundaries is reminiscent of the effect of blocking
cdk5 kinase activity in formation of myotomal muscle
boundaries in the Xenopus embryo. In contrast to embryos
where cdk5 kinase activity has been blocked, a majority of
embryos which have been coinjected with cdk5 WT along
with cdk5 DN, thus rescuing kinase activity, were of
normal size and displayed the usual ordered and regular
organization of both lens and retina. To confirm these
observations we have quantitated the eye defects described
here.
Between 10 and 12 eyes from each class of embryo were
inspected carefully in all planes of section to determine the
proportion that had formed normally. All eyes in the
uninjected and cdk5 WT-injected embryos were normal. In
contrast, of 11 eyes examined in cdk5 DN-expressing em-
bryos, only 2 looked normal, 1 was mildly disrupted, while
8 showed more significant disruption (Fig. 8bii). Four of
these eyes were so substantially disrupted that little struc-
ture could be determined (not illustrated in Fig. 8bii). Of 12
eyes sectioned in embryos which were expressing cdk5 WT
and cdk5 DN together, 9 were entirely normal while the
remaining 3 showed mild disruption (such as the top eye,
Fig. 8biv). This demonstrates that blocking cdk5 kinase
128 Philpott, Tsai, and Kirschner
Copyright © 1999 by Academic Press. All rights of reproduction in any form reserved.
activity specifically results in reduction and disruption of
the embryonic eye and that normal eye structures can be
rescued by restoration of cdk5 kinase activity.
In Fig. 7, we demonstrate that cdk5 DN overexpression is
unable to block induction of neural markers in animal caps.
We have determined that noggin (but not neurogenin) is
able to induce the expression of the eye markers Pax 6 and
Rx (Casarosa et al., 1997; Hirsch and Harris, 1997; Mathers
et al., 1997) in animal caps aged to stage 20 (data not
shown). Overexpression of cdk5 DN (or cdk5 WT) does not
affect the level of Pax 6 or Rx message induced in these
animal caps in response to noggin. From these results we
conclude that the role of cdk5 in eye development is not at
the level of controlling the expression of genes which
coordinate eye development.
We also attempted to investigate the effect of overexpres-
sion of Xp35.2. Overexpression of Xp35.2 even at modest
levels (100 pg) causes cell death at the site of injection.
Lower levels still result in either generalized disruption of
embryonic tissue or have no effect (data not shown). How-
ever, as yet we have been unable to identify conditions
where coinjection of cdk5 DN will rescue this phenotype
(by blocking the activation of cdk5 kinase by the injected
Xp35.2). Thus, we have been unable to determine whether
the cell death and disruption we see on Xp35.2 overexpres-
sion are specific. Interestingly, a construct of Xp35.2 that
codes for only the cdk5 binding and activation domain has
little reproducible effect on embryonic development even at
high levels (data not shown) indicating the functional
importance of the N-terminal domain. The precise role of
this region has yet to be elucidated.
DISCUSSION
Cdk5 has been demonstrated to have an important role in
development and organization of the mammalian nervous
system; a cdk5 null mouse shows perinatal lethality and
displays severe disruption of specific regions in the brain
(Ohshima et al., 1996). It is difficult to determine whether
these represent late patterning defects or whether they are a
manifestation of a much earlier underlying problem in
neural differentiation which appears later as defects in
cortical layering and cerebellar foliation. To determine
whether cdk5 functions in the earliest stages of neural
differentiation and patterning, we have turned to embryos
of the frog X. laevis which provide an excellent system to
study the initial events of neural induction, differentiation,
and patterning, both in the intact early embryo and in
explant cultures.
Unexpectedly, compared to the neural-specific p35 and
p39 mammalian genes so far identified, we cloned two
classes of cdk activator from Xenopus embryos which show
markedly differing expression patterns. Xp35.1 has been
described previously (Philpott et al., 1997) and is found in
both proliferating and differentiating nerve and muscle
cells. In this report we describe a new activator of Xenopus
cdk5, Xp35.2, which in contrast to Xp35.1 is expressed
solely in differentiating neurons. The expression of mam-
malian p35 has been described in detail in older mouse and
rat embryos in regions of the complex central nervous
system of the developing mammalian embryo such as the
cerebral cortex, midbrain, and hindbrain (Delalle et al.,
1997; Zheng et al., 1998). Using Xenopus embryos, we
demonstrate that Xp35.2 expression is pronounced even at
the earliest stage of neurogenesis, namely formation of the
primary neurons which are the first neurons to differentiate
in the embryonic neural plate and which control larval
behavior (Hartenstein, 1989). RT-PCR analysis demon-
strates that overall Xp35.2 expression increases dramati-
cally at stage 23. Jacobson and Huang (1985) have demon-
strated that it is at about this time that pioneer neurons are
growing out in the first neurite outgrowth in the embryo.
Secondary neurite outgrowth in rostral regions is extensive
between stages 24 and 30 when we demonstrate that Xp35.2
is strongly expressed by both RT-PCR and in whole-mount
in situs. Indeed, clearing of the embryos reveals strong
expression of Xp35.2 in all regions of the brain where
extensive neurite outgrowth is occurring. Therefore, ex-
pression patterns indicate that the presence of Xp35.2 is
tightly correlated with neural differentiation and possibly
neurite outgrowth. This contrasts with Xp35.1 which is
expressed in all cells competent to become neurons even
while they are still proliferating. Cdk5 kinase activity does
not seem to be regulated by phosphorylation like the other
cdks (Poon et al., 1997) so levels of kinase activity may be
largely determined by the expression of p35 activating
subunits.
Molecular pathways resulting in neurogenesis in the
early embryo have been investigated extensively using
Xenopus embryos. We wished to establish whether induc-
tion of neural differentiation could lead to activation of
cdk5 kinase. To this end, we injected neurogenin and neuro
D into embryos. These neurogenic genes can induce the
formation of terminally differentiated neurons with elabo-
rated neurites in Xenopus animal caps, neuro D probably
working downstream from neurogenin in the same pathway
(Lee et al., 1995; Ma et al., 1996). We also injected noggin,
an inhibitor of BMP signaling, which is believed to force
cells down a default pathway of neural differentiation but
which alone is unable to induce terminal neural differen-
tiation (Ferreiro et al., 1994; Lamb et al., 1993; Papalopulu
and Kintner, 1996). All three of these neutralizers produce a
robust expression of the neural marker NCAM in animal
caps. However, only neurogenin and neuro D, but not
noggin, were able to activate cdk5 kinase. It is interesting to
note that in the whole embryo Xp35.1 is found over the
entire expanse of the neural plate in both proliferating and
differentiating cells, while the expression of Xp35.2 is
tightly linked to regions of neural differentiation and neu-
rite outgrowth. Neurogenin and neuro D which induce
terminal neural differentiation in the animal cap assay
upregulate the expression of Xp35.2 much more dramati-
cally than Xp35.1 especially at later time points, indicating
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that the expression of Xp35.1 and Xp35.2 is regulated
differently.
It has been reported that noggin alone is unable to induce
the expression of markers of terminal neural differentiation
(Ferreiro et al., 1994; Lamb et al., 1993; Papalopulu and
Kintner, 1996). In the experiment shown here, noggin
injection is able to induce modest expression of the differ-
entiation marker neural b-tubulin even by stage 13 (Fig. 6,
lane 4), although the extent to which this is seen varies
between experiments. This finding could represent subtle
differences in experimental conditions between those used
here and those of other groups (Ferreiro et al., 1994; Lamb et
al., 1993), e.g., noggin level, cap size, precise age at cap
cutting, length of cap aging, and extreme sensitivity of
detection by RT-PCR. In any case, noggin is unable to
induce the expression of Xp35s, cdk5, or cdk5 kinase
activity in the animal cap assay. This could reflect the
inefficiency of noggin at producing differentiated neurons
or could indicate that noggin and neurogenin/neuro D lie on
two different pathways and cdk5 is only responsive to the
pathway controlled by neurogenin. Indeed, even Xp35.1
that is expressed in proliferating neural precursors is not
induced by noggin. It is possible that the lack of cdk5 kinase
activity in animal caps reflects the more anterior nature of
the neural tissue (Papalopulu and Kintner, 1996) induced by
noggin. However, Xp35.1 is expressed in anterior and pos-
terior neural tissue in the intact embryo (Philpott et al.,
1997), but it is still not induced in animal caps by noggin.
In a previous report (Philpott et al., 1997) we have
demonstrated that cdk5 kinase, presumably partnered by
Xp35.1, plays an unexpected role in regulating the expres-
sion of myogenic genes involved in muscle differentiation
and consequently the expression of the muscle marker
muscle actin. To determine whether cdk5 kinase activity
was required for expression of early or late neural marker
genes we injected cdk5 DN along with neurogenin or neuro
D into early embryos. Blocking cdk5 kinase had no discern-
ible effect on expression of NCAM or neural b-tubulin in
animal caps (Fig. 7). This is consistent with a role for
cdk5/Xp35 complexes only in the cytoplasmic events of
neurogenesis, for instance phosphorylation of cytoskeletal
components to promote neurite outgrowth as is proposed in
mammalian systems (Lew and Wang, 1995). Indeed, both
cdk5 and p35 null mice showed primarily disruption of
neural tissue rather than an absence of neurons or an
obvious failure in their ability to differentiate (Chae et al.,
1997; Ohshima et al., 1996). Moreover, cdk5 dominant
negative does not affect expression of eye differentiation
factors Pax 6 and Rx in animal caps in response to noggin
(data not shown). This is in contrast to the role for cdk5
kinase in muscle differentiation in Xenopus which appears
to act at least partly at the level of gene expression (Philpott
et al., 1997).
Dynamic growth and differentiation of neurons are essen-
tial to establish the complex organization of the mamma-
lian brain. However, when loss of a gene such as cdk5
results in loss of organization of CNS structures in well-
developed embryos it is difficult to determine at which
stage the original neural defect arose. Again we have used
the readily accessible embryos of the frog X. laevis to
investigate the role of cdk5 kinase in formation of the
central nervous system at the earliest embryonic stages.
Embryos injected with cdk5 DN showed no obvious defects
in expression of several neural markers, either regional (otx
2, En-2) or global (NCAM, all data not shown). Similarly,
cdk5 DN did not block the expression of neural b-tubulin in
the neural plate which is consistent with its inability to
block neural differentiation in animal caps in response to
neurogenin or neuro D. In some experiments, disruption of
nerves emerging from the trigeminal ganglia was infre-
quently observed (data not shown) which may indicate
some increased sensitivity of these tracts to loss of cdk5
kinase activity and, indeed, these tracts express high levels
of Xp35.2 (Fig. 4). While obvious defects of the neural tube
were not observed, embryos in which cdk5 kinase activity
had been blocked showed substantially reduced eyes, re-
vealed even at early stages of eye formation by staining for
Pax 6 expression (Fig. 8a). These reduced eyes also show
substantial tissue disorganization (Fig. 8b) reminiscent of
the disruption of myotomal muscle seen when cdk5 kinase
activity is blocked in the early embryo.
Reduction in eye size can be a relatively common result
of nonspecific perturbations in the early embryo, most of
which lead to anterior truncations. However, for a number
of reasons we believe that in this case it is a specific effect
of blocking cdk5 kinase activity. First, cdk5 protein is
highly expressed in the eye and Xp35.1 is expressed in the
lens (Philpott et al., 1997) while Xp35.2 is expressed in
differentiating retinal ganglion cells (Fig. 4). These expres-
sion patterns indicate that cdk5 partnered by Xp35.1 and
Xp35.2 is correctly placed to play a role in development of
the eye. The mammalian homologues p35 and p39 are also
found to be strongly expressed in the eye (Zheng et al.,
1998, 1998; Gao et al., 1997). In addition, and most impor-
tantly, the reduced and disrupted eye phenotype produced
by injecting cdk5 DN can be overcome by coexpression of
cdk5 WT which restores cdk5 kinase activity. Such rescue
would only be expected if eye reduction and disruption
were a direct and specific result of blocking cdk5 kinase
activity. Eyes form as outgrowths from the neural tube and
may be reduced when there is an overall reduction in the
size of the neural plate or neural tube. However, cdk5 DN
injection resulted in no obvious reduction in the expanse of
the neural plate at early stages as judged by NCAM staining
(data not shown) making this explanation for reduced eye
size unlikely. The reduction in eye size that we observe
here is consistent with a block in division of the retinal
primordial cells in the early tailbud-stage embryo, although
such a relationship has not been directly demonstrated. It is
unlikely that cdk5 is functioning to titrate cyclin D1 away
from its normal activating kinase (cdk4 or cdk6) during eye
development. If this were the case, overexpression of both
wild-type and dominant negative cdk5 would be expected
to produce embryos with reduced eyes. Moreover, an active
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role for cyclin D1–cdk5 complexes is unlikely as overex-
pression of Xenopus cyclin D1 is unable to rescue the small
eye phenotype produced by overexpression of cdk5 DN
(data not shown).
The expression pattern of Xp35s in differentiating neu-
rons coupled with the experimental work in Xenopus and
mammalian systems indicates that cdk5/p35s function
widely in neural differentiation in the central nervous
system (CNS), yet there are no obvious defects in patterning
or formation of the neural tube in the early Xenopus
embryo. Cdk5/Xp35 may not be essential for neural differ-
entiation in the neural tube at these early stages or other
pathways may compensate for a loss of cdk5 kinase activity
in the brain and spinal cord (but not in the eye). Alterna-
tively, residual cdk5 kinase activity found even in the
presence of cdk5 DN may be enough to allow normal
differentiation, patterning, or neurite outgrowth in the
neural tube while the eye may be particularly sensitive to
cdk5 kinase loss. Given the pleiotropic effects of loss of
cdk5 in the null mouse compared to the limited pleitropy
we see in the frog CNS at these early developmental stages,
it seems likely that other requirements for cdk5 in devel-
opment of the CNS would become apparent in the frog
either if cdk5 kinase activity could be blocked completely
or if more complex aspects of central nervous system
development in the older organism were investigated. The
mouse is a good model for studying the later requirements
for cdk5 in development of CNS structures, for instance, in
cortical layering. The structure of the eye in cdk5 null mice
has not been reported.
The ubiquitous expression of cdk5 and the identification
of two cdk5 activators in frog with quite different expres-
sion patterns indicate a potentially broad role for cdk5
kinase in development of a range of tissues even at early
stages of organization and patterning. It will be interesting
to determine whether more p35 homologues will be iden-
tified which may function in the differentiation and pat-
terning of other embryonic tissues.
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